Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Paratek Pharmaceuticals announces change to time of Annual Meeting » 08:57
05/29/20
05/29
08:57
05/29/20
08:57
PRTK

Paratek Pharmaceuticals

$4.29 /

-0.12 (-2.72%)

Paratek Pharmaceuticals…

Paratek Pharmaceuticals announced its virtual 2020 Annual Meeting of Stockholders will now be held at 9:00 a.m. Eastern Time. The previously announced date of the Annual Meeting, June 10, 2020, will not change. As described in the proxy materials previously distributed for the Annual Meeting, stockholders as of the close of business on April 13, 2020, the record date, may attend the meeting virtually via the Internet at www.virtualshareholdermeeting.com/PRTK2020 by entering the 16-digit control number found in such proxy materials or, for stockholders that hold their shares in "street name," by following the instructions provided by each such stockholder's bank or brokerage firm. Online check-in will begin at 8:45 a.m. Eastern Time, and stockholders should allow ample time for the check-in procedures.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$4.29 /

-0.12 (-2.72%)

PRTK Paratek Pharmaceuticals
$4.29 /

-0.12 (-2.72%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
PRTK Paratek Pharmaceuticals
$4.29 /

-0.12 (-2.72%)

Hot Stocks
Paratek Pharmaceuticals up 2.2% after reporting Q1 results, maintaining guidance  06:53
05/11/20
05/11
06:53
05/11/20
06:53
PRTK

Paratek Pharmaceuticals

$4.65 /

+0.2 (+4.49%)

 
ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$4.65 /

+0.2 (+4.49%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
Earnings
Paratek Pharmaceuticals backs FY20 revenue view of $75M-$80M, consensus $81.12M » 06:53
05/11/20
05/11
06:53
05/11/20
06:53
PRTK

Paratek Pharmaceuticals

$4.65 /

+0.2 (+4.49%)

In evaluating the 2020…

In evaluating the 2020 financial guidance, the company balanced its strong first quarter results against the forecasting challenges related to the COVID-19 pandemic. As a result, Paratek is currently maintaining its full year 2020 financial guidance and will not be making any adjustments at this time.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$4.65 /

+0.2 (+4.49%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
Earnings
Paratek Pharmaceuticals reports Q1 EPS (66c), consensus (80c) » 06:52
05/11/20
05/11
06:52
05/11/20
06:52
PRTK

Paratek Pharmaceuticals

$4.65 /

+0.2 (+4.49%)

Reports Q1 revenue…

Reports Q1 revenue $7.92M, consensus $7.46M. "Demand for NUZYRA continued to increase in the first quarter of 2020 with net revenue growing 35% versus the fourth quarter of 2019, with particular strength seen with the oral formulation. NUZYRA is well-positioned to help address current and future public health emergencies at a time when antibiotic resistance is a growing global threat," said Evan Loh, M.D., CEO. "I would like to thank the entire Paratek team for their dedication and efforts during the COVID-19 pandemic and continuing to drive the business forward, ensuring patients continue to have access to NUZYRA, with its once-daily oral and intravenous formulations, approved for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections."

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$4.65 /

+0.2 (+4.49%)

05/06/20 H.C. Wainwright
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright
04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
Recommendations
Priority Review in China accelerates revenues for Paratek, says H.C. Wainwright » 11:37
05/06/20
05/06
11:37
05/06/20
11:37
PRTK

Paratek Pharmaceuticals

$4.28 /

-0.01 (-0.23%)

, ZLAB

Zai Lab

$61.49 /

+0.09 (+0.15%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Ed Arce notes that Zai Lab (ZLAB), Paratek's (PRTK) collaborative partner which has the exclusive license to develop, manufacture, and commercialize omadacycline for human therapeutic uses in China, announced that China's National Medical Products Administration has granted omadacycline a priority review status to its NDA for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. The analyst regards omadacycline's priority review status as incremental evidence of its potential for CABP and ABSSSI, while he expects the FDA to approve NUZYRA's pre-emergency use authorization application that would enable BARDA's Project BioShield's initial purchase of 2,500 treatment courses of NUZYRA for pulmonary anthrax at a cost of approximately $38M in Q2 as the next major milestone for Paratek. Arce has a Buy rating and a $18 price target on Paratek's shares.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$4.28 /

-0.01 (-0.23%)

04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
12/19/19 SVB Leerink
Paratek should trade 'significantly higher' on BARDA award, says SVB Leerink
ZLAB Zai Lab
$61.49 /

+0.09 (+0.15%)

04/27/20
Zai Lab initiated with a Buy at Goldman Sachs
04/16/20 Guggenheim
Guggenheim starts 'uniquely compelling' Zai Lab at Buy
04/15/20 Guggenheim
Zai Lab initiated with a Buy at Guggenheim
03/02/20 Macquarie
Zai Lab price target raised to $71.46 from $48.32 at Macquarie
Over a quarter ago
Conference/Events
BTIG pharmaceuticals analysts to hold an analyst/industry conference call » 09:55
04/06/20
04/06
09:55
04/06/20
09:55
PRTK

Paratek Pharmaceuticals

$3.22 /

+ (+0.00%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts discuss announced and possible material government purchases of Paratek's Nuzyra on an Analyst/Industry conference call to be held on April 6 at 10:45 am.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$3.22 /

+ (+0.00%)

04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
12/19/19 SVB Leerink
Paratek should trade 'significantly higher' on BARDA award, says SVB Leerink
Conference/Events
BTIG pharmaceuticals analysts to hold an analyst/industry conference call » 04:55
04/06/20
04/06
04:55
04/06/20
04:55
PRTK

Paratek Pharmaceuticals

$3.22 /

+0.22 (+7.33%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts discuss announced and possible material government purchases of Paratek's Nuzyra on an Analyst/Industry conference call to be held on April 6 at 10:45 am.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$3.22 /

+0.22 (+7.33%)

04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
12/19/19 SVB Leerink
Paratek should trade 'significantly higher' on BARDA award, says SVB Leerink
Conference/Events
BTIG pharmaceuticals analysts to hold an analyst/industry conference call » 12:03
04/03/20
04/03
12:03
04/03/20
12:03
PRTK

Paratek Pharmaceuticals

$3.09 /

+0.09 (+3.00%)

Pharmaceuticals Analysts…

Pharmaceuticals Analysts discuss announced and possible material government purchases of Paratek's Nuzyra on an Analyst/Industry conference call to be held on April 6 at 10:45 am.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$3.09 /

+0.09 (+3.00%)

04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
12/19/19 SVB Leerink
Paratek should trade 'significantly higher' on BARDA award, says SVB Leerink
Hot Stocks
Paratek Pharmaceuticals pauses recruitment in ongoing clincial studies » 08:38
04/02/20
04/02
08:38
04/02/20
08:38
PRTK

Paratek Pharmaceuticals

$2.97 /

-0.15 (-4.81%)

The company said,…

The company said, "We applaud the heroic efforts of medical professionals around the world who are working to protect public health and combat the COVID-19 pandemic. Whether directly treating patients impacted by the virus or implementing containment measures to constrain its transmission, you selflessly put the needs and journey of your patients first. We at Paratek will strive to do our part during this crisis. The safety of or employees, the healthcare community and payers is paramount. We are taking appropriate steps to protect our employees, healthcare community and payers, following all local and federal requirements, and continually monitoring the situation to provide the appropriate guidance. Paratek has embraced the public health guidance regarding social distancing with all employees now working from home, utilizing a virtual model for meetings and interactions with the healthcare community and payers. As the global COVID-19 pandemic continues to evolve, to date we have been able to provide an uninterrupted supply of our commercially available antibiotic, NUZYRA Based on current inventory levels and expected demand, we do not currently anticipate a shortage of NUZYRA. Due to the demands on the healthcare system during this unprecedented crisis with COVID-19, the recruitment of our ongoing clinical studies has been paused. At the current time, the only study currently recruiting is our oral only pharmacokinetic study in patients with pneumonia. As the study has not yet completed recruitment, the study will take longer than anticipated. As the situation evolves, we intend to provide future updates on timing of the initiation of recruitment and completion of the study."

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$2.97 /

-0.15 (-4.81%)

04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
12/19/19 SVB Leerink
Paratek should trade 'significantly higher' on BARDA award, says SVB Leerink
Hot Stocks
Paratek announces initiation of funding from BARDA for NUZYRA studies » 08:37
04/02/20
04/02
08:37
04/02/20
08:37
PRTK

Paratek Pharmaceuticals

$2.97 /

-0.15 (-4.81%)

Paratek Pharmaceuticals…

Paratek Pharmaceuticals announced that the Biomedical Advanced Research and Development Authority has initiated funding to support all of the U.S. Food and Drug Administration post-marketing requirements associated with the approval of NUZYRA including pneumonia and pediatric studies as well as the five-year post-marketing bacterial surveillance study. The reimbursement cost for these post-marketing commitments is projected to total approximately $77 million. In connection with the FDA approval of NUZYRA in October 2018, the FDA required that Paratek complete post-marketing pediatric studies examining the safety and efficacy of NUZYRA in children ages eight to 17 years. This includes a pharmacokinetic study as well as safety studies in children with acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia. The FDA also required Paratek conduct an additional safety and efficacy study in adults with CABP. Finally, the FDA required a five-year post-marketing bacterial surveillance study, which is mandatory for all newly approved antibiotics. In December 2019, the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, awarded Paratek a five-year contract, valued at up to $285 million, to support: the development of NUZYRA for the treatment of pulmonary anthrax; all of the U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval; U.S. onshoring and manufacturing security requirements and the procurement of up to 10,000 treatment courses of NUZYRA for the treatment of anthrax. Under the terms of the contract that are now initiated, reimbursement has begun for all of the U.S. Food and Drug Administration post-marketing requirements associated with the initial NUZYRA approval.

ShowHide Related Items >><<
PRTK Paratek Pharmaceuticals
$2.97 /

-0.15 (-4.81%)

04/01/20 H.C. Wainwright
Paratek BARDA funding 'kicks off' Nuzyra onshoring, says H.C. Wainwright
03/24/20 H.C. Wainwright
Paratek, Nabriva can benefit from DISARM Act passage, says H.C. Wainwright
01/08/20 WBB Securities
Paratek Pharmaceuticals initiated with a Speculative Buy at WBB Securities
12/19/19 SVB Leerink
Paratek should trade 'significantly higher' on BARDA award, says SVB Leerink

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.